Test Price
2,800 AEDโ Home Collection Available
CFHR2 Gene Hemolytic Uremic Syndrome (HUS) Genetic Test in UAE | 2800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
This next-generation sequencing test screens the CFHR2 gene for pathogenic mutations causing atypical hemolytic uremic syndrome (aHUS), a severe disorder marked by acute kidney injury, microangiopathic hemolytic anemia, and thrombocytopenia. Results support definitive diagnosis, familial risk stratification, and personalised therapeutic decisions including eculizumab eligibility assessment. All testing adheres to UAE health data protection laws and includes mandatory pre-test and post-test genetic counseling with a board-certified consultant medical geneticist.
Test Overview & Methodology
This genetic test analyses the entire CFHR2 gene for pathogenic variants causing atypical hemolytic uremic syndrome (aHUS), enabling precise diagnosis and familial risk assessment. The test employs next-generation sequencing technology with full exon coverage to detect single nucleotide variants, small insertions and deletions, and copy number variations across the gene.
Sample Type / Matrix:
- Whole blood (EDTA tube)
- Extracted DNA
- FTA card blood spot
Turnaround Time: 3 โ 4 weeks
Price: 2800 AED (inclusive of pre-test genetic counselling)
| Feature | Our Test (Precision / Comprehensive) | Closest Alternative (Sanger Panel) |
|---|---|---|
| Diagnostic Sensitivity | Greater than 99.9% covering SNVs, indels, and CNVs | 85 to 90% mainly point mutations |
| Method | Next Generation Sequencing (Illumina) with full exon coverage | Sanger sequencing of selected exons |
| Reporting Time | 3 to 4 weeks including clinical interpretation | 4 to 6 weeks |
Physician Insight & Safety Protocols
“This CFHR2 genetic test provides critical information for clarifying the underlying cause of atypical hemolytic uremic syndrome and guiding targeted therapies such as eculizumab. It is essential to understand that a negative result does not exclude all genetic forms of aHUS, as mutations in other complement genes may be involved. I strongly recommend reviewing your results with a nephrologist before making any changes to prescribed treatments.”
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication such as antihypertensives, eculizumab, or immunosuppressants without consulting your treating physician. Abrupt cessation may lead to life-threatening disease exacerbation. Always carry a current medication list and review it with your healthcare provider.
Exclusion Criteria and Emergency Red Flags
- Exclusions: Inability to provide informed consent; active hemolytic crisis requiring emergency hospitalisation (sample may be collected after clinical stabilisation); non-attendance at mandatory pre-test genetic counselling session.
- Emergency Red Flags: Sudden severe hypertension; chest pain or dyspnoea; new-onset confusion or seizures; marked decrease in urine output. If any of these occur, seek immediate emergency department care.
Patient FAQ & Clinical Guidance
1. What does a positive CFHR2 mutation result mean?
A positive result indicates a genetic predisposition to atypical hemolytic uremic syndrome. Clinical correlation with renal function, complement activity levels, and family studies are essential for full interpretation. Your consultant medical geneticist will explain the implications for you and your immediate family members.
2. Is this test suitable for children?
Yes, paediatric testing is available with parental or guardian consent and mandatory genetic counselling. All testing for minors complies with UAE data protection regulations and the Federal Decree-Law No. 4 of 2016 on Medical Liability regarding informed consent for clinical procedures.
3. How is the sample collected and will insurance cover the test?
A DHA-certified phlebotomist collects your blood sample at home or at our Dubai Healthcare City facility between 8 AM and 11 PM daily. We verify insurance coverage directly through WhatsApp prior to collection. Our billing team submits claims on your behalf and provides a clear pre-authorisation estimate before any payment is due.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (INT/EGQ/2509DA/3139) and is subject to periodic DHA quality audits.
Clinical & Logistical Metadata
| Test Name | CFHR2 Gene Sequencing for Atypical Hemolytic Uremic Syndrome (aHUS) |
| Price (AED) | 2,800 AED (inclusive of pre-test genetic counselling and clinical report) |
| Turnaround Time | 3 โ 4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted DNA, or FTA card blood spot. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) with full exon coverage including CNV detection |
| ICD-10-CM Code | D59.32 (Atypical hemolytic-uremic syndrome), D59.3 (Hemolytic-uremic syndrome) |
| LOINC Code | 94293-7 (Complement factor H related 2 gene full gene analysis) |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians